Post-kala-azar Dermal Leishmaniasis
📧 Sign up to get email alerts when something new happens for Post-kala-azar Dermal Leishmaniasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Ivermectin Repurposed for the Treatment of PKDL [EARLY_Phase 1]
A Phase 1 trial evaluating repurposed ivermectin for treating Post Kala Azar Dermal Leishmaniasis has been completed.
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: Repurposing Ivermectin for PKDL Treatment [EARLY_Phase 1]
A Phase 1 study evaluated repurposing ivermectin for Post-kala-azar Dermal Leishmaniasis, and the trial has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
A completed study reports the incidence of relapse and Post-kala-azar dermal leishmaniasis in South Sudan among visceral leishmaniasis patie…
-
FDA approval · 2021-05-25FDA Approved: IMPAVIDO — Supplemental Application (Profounda, Inc.)
The FDA approved a supplemental application for IMPAVIDO (miltefosine) filed by Profounda, Inc.
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Miltefosine for Children With PKDL [Phase 3]
Phase 3 clinical trial update for miltefosine in children with Post Kala Azar Dermal Leishmaniasis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-10-17Clinical Trial Update: Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh [Phase 4]
This Phase 4 trial evaluated a short course of AmBisome (liposomal amphotericin B) for treating post-kala-azar dermal leishmaniasis (PKDL) i…
-
FDA approval · 2015-04-10FDA Approved: IMPAVIDO — Supplemental Application (Profounda, Inc.)
FDA approved a supplemental application for IMPAVIDO (miltefosine) filed by Profounda, Inc.
-
CLINICAL_TRIALS trial_result · 2015-04-03Clinical Trial Update: Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India [Phase 1]
Phase 1 open-label safety study of a three-antigen Leishmania polyprotein vaccine with MPL-SE adjuvant in healthy adults in India; the trial…
-
CLINICAL_TRIALS trial_result · 2014-11-05Clinical Trial Update: A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) [Phase 4]
A Phase 4 clinical trial completed in Bangladesh evaluated how different treatment regimens for visceral leishmaniasis, along with host immu…
-
FDA approval · 2014-03-19FDA Approved: IMPAVIDO — Original Application (Profounda, Inc.)
FDA approved IMPAVIDO (miltefosine) through Profounda, Inc. via Original Application (NDA204684) for visceral leishmaniasis and post-kala-az…
-
CLINICAL_TRIALS trial_result · 2012-07-10Clinical Trial Update: Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) [Phase 2]
Phase 2 clinical trial evaluating oral miltefosine for safety and efficacy in post-kala-azar dermal leishmaniasis (PKDL) has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-27Clinical Trial Update: Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL [Phase 1]
Phase 1 trial evaluating the safety and immunogenicity of LEISH-F2 + MPL-SE vaccine with SSG in patients with post-kala-azar dermal leishman…